⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857246 | 1.00 | — | — | |
| SCHEMBL371486 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL3339455 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL1849613 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL560334 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL594309 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL765400 | 1.00 | — | — | |
| SCHEMBL3339811 | 1.00 | — | — | |
| SCHEMBL13894718 | 1.00 | CA1 (0.53) | — | |
| SCHEMBL1773898 | 1.00 | CA1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0080658-B1 | PROCESS FOR PRODUCING CYCLIC 1,2-CIS DIOLS FROM CYCLIC 1,2-EPOXIDES | BAYER AG (DE) | 1987-09-30 | — | — | EP | claimed |
| EP-0080658-A1 | Process for producing cyclic 1,2-cis diols from cyclic 1,2-epoxides | BAYER AG (DE) | 1983-06-08 | — | — | EP | claimed |
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180264089-A1 | MODIFIED IDURONATE 2-SULFATASE AND PRODUCTION THEREOF | SWEDISH ORPHAN BIOVITRUM AB (PUBL) (SE) | 2018-09-20 | — | — | US | disclosed |
| US-20180258408-A1 | MODIFIED LYSOSOMAL PROTEIN AND PRODUCTION THEREOF | SWEDISH ORPHAN BIOVITRUM AB (PUBL) (SE) | 2018-09-13 | — | — | US | disclosed |
| EP-3355912-A1 | MODIFIED IDURONATE 2-SULFATASE AND PRODUCTION THEREOF | Swedish Orphan Biovitrum AB (Publ) (SE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| WO-2007082026-A2 | CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES | THE TRUSTEES OF BOSTON COLLEGE (US) | 2007-07-19 | — | — | WO | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0080658-B1 | PROCESS FOR PRODUCING CYCLIC 1,2-CIS DIOLS FROM CYCLIC 1,2-EPOXIDES | BAYER AG (DE) | 1987-09-30 | — | — | EP | disclosed |
| EP-0080658-A1 | Process for producing cyclic 1,2-cis diols from cyclic 1,2-epoxides | BAYER AG (DE) | 1983-06-08 | — | — | EP | disclosed |